Benzinga

Benzinga

Benzinga

lunes, agosto 24

Vertex Pharmaceuticals Inc

VRTXNASDAQ
Trade with Public
Trade with Public
$548.05
7.791.44%
al cierre: Aug 20, 5:00 PM EST
$548.05
7.791.44%
Premercado: 6:50 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararOpcionesInforme de acciones

Vertex Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vertex Pharmaceuticals (VRTX).

Price Target Range — 7 Quarters

Analyst Consensus — 27 Analysts

21Buy
5Hold
1Sell
Consensus RatingBuy# Analysts27Avg. Consensus PT$540Upside to Avg. PT-1.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 5, 2026Truist SecuritiesDanielle BrillPT RaiseBuy$560→$565
Aug 5, 2026BarclaysEliana MerlePT RaiseOverweight$615→$617
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617

Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550

TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595

Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585

UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $545 to $585.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved